What this means
Researchers plan to give some older adults 200 mg of CoQ10 daily and others a placebo for 10 weeks. No results are available yet, so we do not know if it helps.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 65 and over
- Where
- Not listed
The science
- Registered title
- MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10
- Trial ID
- NCT07772336 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Frailty, Aging, Mitochondria Health, Skin Aging, Mitochondrial Dysfunction
- What is tested
- Q10Vital® (CoQ10, ubiquinone), Placebo
- Sponsor
- University Medical Centre Ljubljana
- Ages
- 65 Years to no maximum
- Dates
- First posted Aug 19, 2026 · updated Aug 19, 2026
Registry summary
This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty.
Participants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The study will assess the effects of CoQ10 supplementation on mitochondrial functional resilience, chronic low-grade inflammation, metabolic health, physical performance, cognitive function, and objective measures of skin aging.
The study will also investigate whether baseline biological and functional characteristics can identify individuals who are more likely to benefit from CoQ10 supplementation. An exploratory aim is to develop a multidimensional composite index of biological resilience integrating molecular, biochemical, functional, and clinical measures of aging.
The study will provide evidence on whether a mitochondria-targeted intervention with CoQ10 may represent a potential strategy for improving functional resilience and reducing features of prefrailty in older adults.